PLoS ONE (Jan 2022)

Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.

  • Kristin G-I Mohn,
  • Geir Bredholt,
  • Fan Zhou,
  • Anders Madsen,
  • Therese B Onyango,
  • Elisabeth B Fjelltveit,
  • Sarah L Jalloh,
  • Karl A Brokstad,
  • Diego Cantoni,
  • Martin Mayora-Neto,
  • Nigel Temperton,
  • Nina Langeland,
  • Rebecca J Cox,
  • Bergen COVID-19 research group

DOI
https://doi.org/10.1371/journal.pone.0261979
Journal volume & issue
Vol. 17, no. 2
p. e0261979

Abstract

Read online

BackgroundNeutralizing antibodies are important for protection against the pandemic SARS-CoV-2 virus, and long-term memory responses determine the risk of re-infection or boosting after vaccination. T-cellular responses are considered important for partial protection against novel variants of concern.MethodsA prospective cohort of hospitalized (n = 14) and community (n = 38) patients with rt-PCR confirmed SARS-CoV-2 infection were recruited. Blood samples and clinical data were collected when diagnosed and at 6 months. Serum samples were analyzed for SARS-CoV-2-spike specific antibodies using ELISA (IgG, IgA, IgM), pseudotype neutralization and microneutralization assays. Peripheral blood mononuclear cells were investigated for virus-specific T-cell responses in the interferon-γ and interleukin-2 fluorescent-linked immunosorbent spot (FluroSpot) assay.ResultsWe found durable SARS-CoV-2 spike- and internal protein specific T-cellular responses in patients with persistent antibodies at 6 months. Significantly higher IL-2 and IFN-γ secreting T-cell responses as well as SARS-CoV-2 specific IgG and neutralizing antibodies were detected in hospitalized compared to community patients. The immune response was impacted by age, gender, comorbidity and severity of illness, reflecting clinical observations.ConclusionsSARS-CoV-2 specific T-cellular and antibody responses persisted for 6 months post confirmed infection. In previously infected patients, re-exposure or vaccination will boost long-term immunity, possibly providing protection against re-infection with variant viruses.